SCHEMBL11958239

SCHEMBL11958239

Cc1ccc(S(=O)(=O)N2CCN(c3ccc(Cl)cc3Cl)C(c3ccc(Cl)cc3)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.49
HTT P42858 4/20 0.47
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ATM Q13315 1/20 0.46
PKM P14618 5/20 0.45
POLB P06746 2/20 0.45
USP2 O75604 1/20 0.44
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
LMNA P02545 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PKLR P30613 1/20 0.43
GFER P55789 1/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11958256 0.94 ATM (0.48) HTTALDH1A1ATMPKMPOLB
SCHEMBL11958263 0.89 MCOLN3 (0.46) HTTALDH1A1ATMPKMPOLB
SCHEMBL11958290 0.89 ATM (0.43) HTTALDH1A1ATMPKMPOLB
SCHEMBL11958243 0.89 SMN1; SMN2 (0.48) HTTALDH1A1NPSR1ATMPKM
SCHEMBL11957719 0.89 ALDH1A1 (0.47) HTTALDH1A1KDM4ENPSR1ATM
SCHEMBL11958246 0.89 THRB (0.50) HTTALDH1A1ATMPKMPOLB
SCHEMBL11958249 0.89 ALDH1A1 (0.53) HTTALDH1A1KDM4EPKMPOLB
SCHEMBL11958238 0.89 LMNA (0.46) DPP4HTTALDH1A1POLBUSP2
SCHEMBL11958272 0.89 HSD11B1 (0.55) HTTALDH1A1NPSR1ATMPOLB
SCHEMBL11958283 0.88 HSD11B1 (0.44) HTTALDH1A1ATMPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236805-B2 Substituted piperazines as CB1 antagonists INTERVET INC. (US) 2012-08-07 US disclosed
US-7700597-B2 Substituted piperazines as CB1 antagonists SCHERING CORPORATION (US) 2010-04-20 US disclosed
US-7700597-B2 Substituted piperazines as CB1 antagonists SCHERING CORPORATION (US) 2010-04-20 US disclosed
US-20100029607-A1 Substituted Piperazines as CB1 Antagonists SCHERING CORPORATION 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029607-A1 Substituted Piperazines as CB1 Antagonists CNR1, CNR2, GPR119 DPP4 2186/4885HTT 1252/4885ALDH1A1 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.